Tammy Sarnelli - Amylyx Pharmaceuticals Global Affairs
| AMLX Etf | USD 3.65 0.08 2.14% |
| Phone | 617 682 0917 |
| Web | https://amylyx.com |
Amylyx Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5131) % which means that it has lost $0.5131 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0088) %, meaning that it created substantial loss on money invested by shareholders. Amylyx Pharmaceuticals' management efficiency ratios could be used to measure how well Amylyx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Fund Executives
| Showing other executives | One Year Return | ||
| Suba Krishnan | Mereo BioPharma Group | 60 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Gregory Conn | PDS Biotechnology Corp | 70 | |
| MS MBA | PDS Biotechnology Corp | 59 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Emil MD | Terns Pharmaceuticals | 45 | |
| Deanne Randolph | PDS Biotechnology Corp | N/A | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| JD Esq | Acumen Pharmaceuticals | 54 | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Spencer JD | PDS Biotechnology Corp | 55 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| James Kanter | Terns Pharmaceuticals | N/A | |
| FASCP MD | Inozyme Pharma | 70 | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.01 | ||||
| Return On Asset | -0.51 |
Amylyx Pharmaceuticals Money Managers
| Debra Canner, Global CHRO | ||
| Margaret MBA, Global Officer | ||
| Shauna Horvath, Head Marketing | ||
| Gina JD, Chief Counsel | ||
| Chris Aiello, Head GM | ||
| Machelle Manuel, VP Affairs | ||
| Justin Klee, CoCEO CoFounder | ||
| Camille MD, Chief Officer | ||
| James MBA, Chief Officer | ||
| MD MBA, Global Officer | ||
| Tammy Sarnelli, Global Affairs | ||
| Joshua Cohen, CoCEO CoFounder | ||
| Tom Holmes, Chief Officer | ||
| Gina Mazzariello, Chief Counsel | ||
| Keith White, Head Access | ||
| Lindsey Allen, Head Communications | ||
| Linda Arsenault, Chief Officer |
Amylyx Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Amylyx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.01 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | 61.13 % | ||||
| Current Valuation | 148.88 M | ||||
| Shares Outstanding | 88.6 M | ||||
| Shares Owned By Insiders | 11.69 % | ||||
| Shares Owned By Institutions | 65.72 % | ||||
| Number Of Shares Shorted | 3.38 M | ||||
| Price To Book | 1.96 X | ||||
| Price To Sales | 3.78 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.